Healthcare / Elderly CareUS
← Sticker Wall
JOURNEY · DETAIL
Medtronic: From a Minnesota garage repair shop inventing the world's first battery-powered pacemaker to becoming the world's largest medical device company
Founded: Earl Bakken, Palmer Hermundslie · Medtronic plc
JOURNEY
Key Fields
FIELD STAMPSIndustryHealthcare / Elderly Care
RegionUS
ScaleGiant
ChannelOther
Origin
In 1949, electrical engineering graduate student Earl Bakken and his brother-in-law Palmer Hermundslie founded Medtronic in the back room of a train garage in Minneapolis. Initially focused on repairing hospital medical electronic equipment, their first month's revenue was just 8 dollars. The turning point came in October 1957 following a request from C. Walton Lillehei, a cardiothoracic surgeon at the University of Minnesota Hospital: a hospital power outage had caused a mains-powered pacemaker to fail, resulting in the death of a pediatric patient. Lillehei asked Bakken to develop a battery-powered pacemaker. Working for only four weeks and referencing a transistor metronome circuit from Popular Electronics magazine, Bakken built the world's first wearable, battery-powered external pacemaker, transforming the company from a repair shop into a medical innovation enterprise.
Milestones
1949
Garage Beginnings Failure
In 1949, Bakken and Hermundslie established Medtronic in the back room of a train garage for medical equipment repair. Their first month in business yielded only 8 dollars from repairing a single centrifuge. For the first few years, they operated at a continuous loss, relying on deferred employee wages and asset sales to survive. Bakken later recalled that the company came close to closing down several times while burdened with heavy debt.
1957
Defining Invention Turning Point
In late October 1957, a major blackout in St. Paul caused the death of Dr. Lillehei's postoperative pediatric patient due to a power failure in the AC-powered pacemaker. The doctor implored Bakken to develop a battery-driven solution. Within four weeks, Bakken designed a wearable external cardiac pacemaker based on a transistor circuit from a magazine. By the following year, it went on sale across the United States, propelling the company from a repair shop into high-value medical electronics manufacturing.
1960
Technology Licensing PMF
In 1960, Medtronic signed an exclusive licensing agreement with electrical engineer Wilson Greatbatch, inventor of the implantable pacemaker circuit, acquiring the intellectual property for implantable pacemakers. This marked Medtronic's entry into the core sector of internal implantable devices, securing its industry-leading position in pacemakers throughout the 1960s and establishing its cash flow foundation in the U.S. market.
1976
Standardization and IPO Growth
Bakken stepped back to let professional managers, preceding Bill George, take the helm. The company comprehensively overhauled its quality and compliance systems. Medtronic subsequently went public, leveraging equity financing to move away from a family workshop model into a period of scaled expansion. This laid the capital foundation for global M&A over the next four decades, a phase spanning from 1976 to 1977.
1998
Aggressive M&A Growth
In 1998, Medtronic acquired spinal device company Sofamor Danek for approximately 3.7 billion dollars, alongside several orthopedic and vascular intervention companies that same year. This expanded the company from a single cardiac rhythm business into a multi-specialty device platform, with annual revenue surpassing the 2 billion dollar milestone and officially cementing its top-tier status in comprehensive medical devices.
2001
Expansion and Hidden Risks Failure
The company acquired MiniMed to enter the diabetes business, but concurrently, its Infuse bone graft protein product faced a U.S. Senate investigation for over-promotion of off-label use and the concealment of complication data. This ultimately led to massive litigation settlement costs, marking one of the most notable compliance debacles in company history, a phase lasting from 2001 to 2011.
2015
Largest Acquisition in History Turning Point
In 2015, Medtronic acquired Covidien for approximately 42.9 billion dollars and relocated its legal headquarters to Ireland. At the time, this was the largest merger and acquisition in the medical device industry. Following the merger, revenue temporarily surpassed Johnson & Johnson's device business to become industry number one. However, the corporate inversion drew intense domestic U.S. criticism, and tightening regulations placed a heavy integration burden on the company.
2018
Integration and Digestion Growth
Medtronic continuously digested surgical robotics assets such as Covidien and Mazor. Fiscal year 2024 revenue reached approximately 32.4 billion dollars with around 95,000 employees, while simultaneously cutting costs and planning the spinoff and IPO of its diabetes business. The company shifted its focus from pursuing scale to prioritizing profitability quality, maintaining a market capitalization above 100 billion dollars across this phase from 2018 to 2024.
Turning Points
- The 1957 power outage gave rise to the battery-powered pacemaker, turning an urgent rescue request into an invention company from a repair shop.
- Securing the exclusive license for Greatbatch's implantable pacemaker in 1960 locked down a decades-long lifeline in the internal implant sector in one stroke.
- Multi-billion-dollar acquisitions in the late 1990s broke into the spine field, upgrading the company from a single-product firm to a multi-specialty platform.
- The 42.9 billion dollar acquisition of Covidien and redomiciling to Ireland in 2015 propelled the company to industry number one while saddling it with both integration and public relations burdens.
Failures & Pitfalls
- Income fell short of expenses during the startup phase, making only 8 dollars in the first month and bringing the company close to bankruptcy multiple times within the first few years, relying on the founders taking on debt to survive.
- Infuse bone graft protein faced Senate investigations and massive litigation due to off-label promotion and concealed risk data, severely damaging the company's reputation.
- The 2015 redomiciling to Ireland was criticized by the U.S. government and public as a tax inversion, triggering stricter regulations and pushing M&A integration costs far beyond expectations.
- Following ballooning scale, managerial complexity surged, forcing the company to restructure, downsize, and spin off its diabetes business in the 2020s to regain capital market trust.
关键成功要素
- Using electrical engineering skills to solve immediate hospital pain points that no one else wanted to touch; staying close to the clinical frontlines enabled them to answer doctors' cries for help immediately.
- Defending a monopolistic position in pacemakers through exclusive tech licensing and sustained R&D investment, turning a one-time life-saving product into a repeat-purchase material business.
- Driving massive M&A with a continuous stream of cash flow, outsourcing the challenge of a single-sector ceiling to external expansion.
- The mission and values of alleviating pain, written into the company DNA by Bakken, shaped a cultural foundation of long-term trust among doctors, patients, and employees.
Lessons
- Inventors must first survive on repair fees before talking about ideals; cash flow and sheer time alive constitute a moat in themselves.
- Key technologies can be bought out through licensing rather than requiring everything to be self-developed, but you must move first to lock in exclusivity.
- The greatest risk in medical devices lies not in technology, but in compliance; commercial victories can be instantly wiped out by a single whistleblower and concealed data.
- Scale M&As can buy market leadership, but they cannot buy organizational health. A second growth curve must be paired with internal downsizing.
Core Data
- Revenue in first month of 1949 startup：8 dollars (public data basis, independent verification unconfirmed)
- 2015 Covidien acquisition transaction value：42.9 billion dollars (public data basis, independent verification unconfirmed)
- Fiscal year 2024 revenue：approx. 32.4 billion dollars (public data basis, independent verification unconfirmed)
- Total number of employees：approx. 95,000 (public data basis, independent verification unconfirmed)
- Brand history：Founded in 1949, over 85 years old (public data basis, independent verification unconfirmed)
- Pioneering product：Created the world's first battery-powered external cardiac pacemaker in 1957 (public data basis, independent verification unconfirmed)
Competitors / Peers
Medtronic's long-term benchmarking peers include giants such as Johnson & Johnson MedTech, Boston Scientific, Abbott, and Siemens Healthineers. Johnson & Johnson rivals its scale for industry leadership; Boston Scientific continuously chips away at market share in cardiac intervention; Abbott directly competes in cardiac rhythm and diabetes management continuous glucose monitoring; and Siemens Healthineers dominates the high-end market for imaging equipment. Medtronic's unique competitive advantages over peers include its identity as the inventor of the pacemaker, the broadest medical specialty coverage, and deep physician loyalty built through its implantable device ecosystem.